1.	Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SUGEN-SU5416.031, CDR0000067499, UCLA-9909008, NCT00004252
2.	Phase III Randomized Study of Fluorouracil, Leucovorin Calcium, and Irinotecan With or Without SU5416 in Patients With Previously Untreated Metastatic Colorectal Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-001003701, SUGEN-SU5416.035, NCI-G01-1980, NCT00021281
3.	Phase I/II Study of SU5416 with Fluorouracil and Leucovorin Calcium in Patients with Metastatic Colorectal Cancer (Summary Last Modified 01/2000) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Over 18 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-9901075, SUGEN-SU5416.010, NCI-G99-1546
4.	Phase I/II Study of SU5416 in Patients With Recurrent High-Grade Astrocytoma or Mixed Glioma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NABTC-9902, MSKCC-01045, NCI-00-C-0173, NABTC-99-02, NCT00004868
5.	Phase I/II Study of Daunorubicin Liposomal and SU5416 in Patients With Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts (RAEB), RAEB in Transformation, or Chronic Myelomonocytic Leukemia Refractory to Induction Chemotherapy (Summary Last Modified 05/2001) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MDA-ID-99341, NCI-673, NCT00005942, 673
6.	Phase I/II Study of SU5416 and Irinotecan in Patients With Advanced Colorectal Carcinoma (Summary Last Modified 04/2002) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MDA-ID-99243, NCI-88, NCT00005818, 88
7.	Phase I/II Randomized Study of Neoadjuvant Radiotherapy With or Without SU5416 in Patients With Stage IB or IIA Soft Tissue Sarcoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-S-0120, NCT00023725
8.	Phase I/II Study of Neoadjuvant Chemotherapy Plus SU5416 and Radiotherapy Followed By Surgical Resection and Adjuvant Chemotherapy Plus SU5416 in Patients With High-Grade Stage IIC-III Soft Tissue Sarcoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-S-0121, NCT00023738
9.	SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067633, AMC-022, NCT00005042
10.	Phase II Study of SU5416 in Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor (Summary Last Modified 04/2002) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: DFCI-00002, NCI-330, NCT00005862, 330
11.	Phase II Study of SU5416 in Patients With Advanced Colorectal Cancer (Summary Last Modified 05/2001) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-NCI-52, 10411, NCI-52, NCT00006001, 52
12.	SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000068010, UCCRC-10428, UCCRC-NCI-49, NCI-49, 49, NCT00006002
13.	Phase II Study of SU5416 in Patients With Previously Treated Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-10395, NCI-48, NCT00006003, 48
14.	Phase II Study of SU5416 in Patients With Refractory or Relapsed Multiple Myeloma (Summary Last Modified 05/2002) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: FCCC-00009, NCI-58, NCT00006013, 58
15.	Phase II Study of SU5416 in Patients With Unresectable Malignant Mesothelioma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-10409, UCCRC-NCI-44, NCI-44, NCT00006014, 44
16.	Phase II Study of SU5416 in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-00049, NCI-79, NCT00006361, 79
17.	SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 00041, U01CA062505, P30CA033572, CHNMC-PHII-23, NCI-T99-0085, CDR0000068262, T99-0085, NCT00006384
18.	Phase II Study of SU5416 in Patients With Progressive Metastatic Renal Cancer Failing Prior Biologic Therapy or Fluorouracil-Containing Regimens Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: MDA-ID-99291, NCI-1290, NCT00009919, 1290
19.	Phase II Study of Thalidomide and SU5416 in Patients With Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UTHSC-IDD-99-27, SACI-IDD-99-27, NCI-66, NCT00017316, 66
20.	Phase II Study of SU5416 in Patients With Persistent or Recurrent Cervical Squamous Cell Carcinoma Phase: Phase II Type: Treatment Status: Completed Age: Not specified Sponsor: NCI Protocol IDs: GOG-0227B, NCT00026260
21.	SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SUGEN-SU5416.003, CDR0000066829, LAC-USC-17K981, NCT00003720
22.	SU5416 in Treating Patients With Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CWRU2Y99, U01CA062502, P30CA043703, NCI-T99-0095, T99-0095, NCT00005642
23.	SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CWRU5199, U01CA062502, P30CA043703, NCI-T99-0099, T99-0099, NCT00005822
24.	SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CWRU1399, U01CA062502, P30CA043703, NCI-T99-0084, T99-0084, NCT00005647
25.	Phase I Study of SU5416 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors (Summary Last Modified 09/2000) Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0002046, SUGEN-ND019901/SE5416.102, NCI-G00-1805, NCT00005996